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Abstract
Background: Heparanase, a mammalian endo-b-D-glucuronidase, specifically degrades heparan sulfate proteoglycans
ubiquitously associated with the cell surface and extracellular matrix. This single gene encoded enzyme is over-expressed in
most human cancers, promoting tumor metastasis and angiogenesis.
Principal Findings: We report that targeted disruption of the murine heparanase gene eliminated heparanase enzymatic
activity, resulting in accumulation of long heparan sulfate chains. Unexpectedly, the heparanase knockout (Hpse-KO) mice
were fertile, exhibited a normal life span and did not show prominent pathological alterations. The lack of major
abnormalities is attributed to a marked elevation in the expression of matrix metalloproteinases, for example, MMP2 and
MMP14 in the Hpse-KO liver and kidney. Co-regulation of heparanase and MMPs was also noted by a marked decrease in
MMP (primarily MMP-2,-9 and 14) expression following transfection and over-expression of the heparanase gene in cultured
human mammary carcinoma (MDA-MB-231) cells. Immunostaining (kidney tissue) and chromatin immunoprecipitation
(ChIP) analysis (Hpse-KO mouse embryonic fibroblasts) suggest that the newly discovered co-regulation of heparanase and
MMPs is mediated by stabilization and transcriptional activity of b-catenin.
Conclusions/Significance: The lack of heparanase expression and activity was accompanied by alterations in the expression
level of MMP family members, primarily MMP-2 and MMP-14. It is conceivable that MMP-2 and MMP-14, which exert some of
the effects elicited by heparanase (i.e., over branching of mammary glands, enhanced angiogenic response) can
compensate for its absence, in spite of their different enzymatic substrate. Generation of viable Hpse-KO mice lacking
significant abnormalities may provide a promising indication for the use of heparanase as a target for drug development.
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Introduction
Studies on the involvement of extracellular matrix (ECM)
molecules in cell attachment, growth and differentiation revealed
a central role of heparan sulfate proteoglycans (HSPGs) in
embryogenesis, morphogenesis, angiogenesis and epithelial-mesen-
chymal interactions [1,2,3]. Heparan sulfate (HS) chains interact
with a multitude of proteins and ensure that a wide variety of
bioactive molecules (e.g.-growth factors, chemokines, lipoproteins,
enzymes) bind to the cell surface and ECM. HSPGs can thus
influence a number of normal and pathological processes, among
which are tissue repair, neurite outgrowth, inflammation and
autoimmunity, tumor growth and metastasis, vasculogenesis and
angiogenesis [1,2,3,4,5]. The ECM provides an essential physical
barrier between cells and tissues, as well as a scaffold for cell growth,
migration, differentiation and survival. It undergoes continuous
remodeling during development and in certain pathological
conditions such as wound healing, inflammation and cancer [6].
Cleavage of HS side chains is therefore expected not only to alter
thestructural integrityoftheECM, butalsoto release andmodulate
the activities of HS-bound biological mediators [4].
Mutational studies in drosophila and targeted disruption of
murine genes involved in HS biosynthesis, or encoding HSPG
core proteins, have demonstrated a critical role for HSPGs in
developmental processes [7,8,9]. The observed phenotypes vary
dramatically in severity, from failure to gastrulate [10] to selective
impairment of mast cell function in otherwise seemingly healthy
mice [11].
Heparanase is an endo-b-D-glucuronidase capable of cleaving
HS side chains at a limited number of sites [12,13,14]. Heparanase
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metastatic potential of tumor-derived cells, attributed to enhanced
cell dissemination as a consequence of HS cleavage and
remodeling of the ECM barrier [14,15]. Similarly, heparanase
activity is implicated in neovascularization, inflammation and
autoimmunity, involving migration of vascular endothelial cells
and activated cells of the immune system [14,15,16]. Moreover,
heparanase upregulation correlates with increased tumor vascu-
larity and poor post-operative survival of cancer patients
[17,18,19,20].
The present study focuses on the generation of heparanase
deficient mice by gene targeting. Despite complete lack of
heparanase gene expression and enzymatic activity, the mice
developed normally, were fertile and did not exhibit apparent
anatomical and functional abnormalities, presumably because
heparanase deficiency was compensated in most organs (i.e., liver,
kidney) by a marked elevation in the expression of matrix
metalloproteinase i.e., MMP-9 and MMP-14 family members.
This newly discovered association between heparanase and MMPs
suggests a combined interdependent control mechanism regulating
the basal level of ECM degrading enzymes in cells and tissues.
Materials and Methods
Gene targeting construct
A 15-kb genomic clone containing the 59 end of the heparanase
gene (Hpse) was isolated from a bacteriophage mouse (strain 129/
Sv) genomic library (Stratagene, Cedar Creek, TX). A 2.5-kb
fragment upstream of exon 1 was cloned, as the short homologous
arm, into pNT-Lox2 plasmid (kindly provided by Dr. Peter
Carmeliet, Department of Molecular and Cellular Medicine,
Catholic University, Leuven, Belgium) downstream of the
neomycin resistance gene (neo cassette). A 4.8-kb fragment
downstream of exon 1 was cloned upstream of the neo cassette as
the long homologous arm of the endogenous gene. The targeting
vector construct had a total size of about 14.5-kb.
Homologous recombination in ES cells and generation of
heparanase deficient mice
The targeting vector was linearized by the restriction enzyme
Not I and electroporated into R1 embryonic stem (ES) cells.
Clones expressing the neo-resistant gene were selected by including
G418 (350 mg/ml; Invitrogen, Carlsbad, CA) in the cell culture
medium and analyzed for target gene homologous recombination
by Southern blot analysis of genomic DNA. The positive clones
were injected into C57BL/6 blastocysts, and chimeric male
founder mice were crossed with C57BL/6 females. Heterozygous
mice were further crossed for 10 generations with C57BL/6J mice
to produce Hpse-KO mice on a C57BL/6J background. All animal
experiments were conducted in compliance with the Swedish and
the Israeli legislation for animal welfare. All the animal
experiments were approved by the animal committees of the
Hebrew University, Jerusalem Israel (MD-89.49-4) and the
Biomedical Center, University of Uppsala, Sweden (C176/2)
according to the NIH guidelines.
Genotype analysis
The genotype was determined by Southern blot analysis and
PCR. Briefly, genomic DNA extracted from ES cells or tail
biopsies was digested with either EcoRV or Sca1. The resulting
fragments were separated on 0.8% agarose gels and blotted onto a
Nylon membrane, followed by hybridization with
32P-labeled
probe #3, as shown in Figure 1A.
Detection of gene expression
Total RNA was isolated from about 100 mg tissue using TRIzol
(Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions, and quantified by spectrophotometry. After oligo
(dT)-primed reverse transcription of 500 ng of total RNA, the
resulting single stranded cDNA was amplified using the primers
listed in Table 1. PCR conditions for heparanase were
denaturation for 2 min at 94uC followed by 25 cycles of
denaturation for 15 seconds at 94uC, annealing for 1 min at
58uC, and extension for 1 minute at 72uC. Aliquots (10 ml) of the
amplified products were separated by electrophoresis on a 1.5%
agarose gel and visualized by ethidium bromide staining (Hy Labs,
Rehovot, Israel). The primers used for PCR are summarized in
Table 1.
Preparation of ECM coated dishes
Bovine corneal endothelial cells were established and cultured
as described [21]. For preparation of sulfate-labeled ECM, corneal
endothelial cells were cultured in the presence of Na2[
35S]O4 (GE
Healthcare Bioscience, Uppsala, Sweden) added (25 mCi/mL) on
days 1 and 5 after seeding. Seven to 10 days later, the cell
monolayer was dissolved and the ECM exposed, as described
[21,22].
Heparanase activity
Heparanase enzymatic activity was determined in blood
samples and tissue extracts derived from heparanase deficient
(Hpse -KO) and wild type (wt) mice. Serum samples were diluted
1:1 in reaction buffer (20 mM phosphate–citrate buffer pH 6.2,
containing 1 mM dithiothreitol, 1 mM CaCl2, and 50 mM NaCl)
and incubated (16 h, 37uC) with
35S-labeled ECM, prepared as
described above. The incubation medium was centrifuged
(20,0006g, 4uC, 1 min), and the supernatant containing
35S-
labeled HS degradation fragments was analyzed by gel filtration
on a Sepharose CL-6B column. Fractions (0.2 mL) were collected
and the amount of radioactivity in each fraction was counted in a
beta scintillation counter. Nearly intact HSPGs were eluted from
Sepharose 6B just after the void volume (peak I, Kav,0.2), while
HS degradation fragments are eluted towards the Vt of the column
(peak II, 0.5,kav,0.8) [4,22,23].
For analysis of heparanase activity in tissue samples, 4 month
old wt and Hpse-KO mice were sacrificed, and the organs were
immediately homogenized in 2 ml PBS, pH 7.4, containing 1%
Triton X-100 and a protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO). The homogenates were incubated on ice for 30 min
followed by centrifugation at 4uC, 15,000 rpm for 20 min. The
supernatant was loaded onto a HiTrap heparin-Sepharose (GE
Healthcare Bioscience) column equilibrated in the homogeniza-
tion buffer. After washing with 10 ml PBS, the bound material was
eluted with PBS containing 1M NaCl. The total amount of protein
was determined by the Bradford method [24]. Samples of 50 mg
protein from the elution were incubated (37uC, overnight) with
5,000 cpm [
3H]acetyl-labeled HS in 20 mM phosphate-citrate
buffer, pH 5.8, 1 mM dithiothreitol, 1 mM CaCl2, and 50 mM
NaCl. The resulted products were analyzed by gel chromatogra-
phy on Superose-12 column (GE Healthcare Biosciences).
Metabolic radiolabeling and isolation of HSPG/HS
Wild type and Hpse-KO mice were injected intra-peritoneally
with 0.5 mCi Na2
35SO4 (specific activity 1,500 Ci/mmol; Perkin
Elmer, Waltham, MA) and maintained for 45 min with free access
to water and food. The animals were then sacrificed by cervical
dislocation and the organs were dissected. The tissues were
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PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5181Co-Regulation of Hpse & MMPs
PLoS ONE | www.plosone.org 3 April 2009 | Volume 4 | Issue 4 | e5181homogenized with a Dounce homogenizer in 6 volumes of ice-cold
50 mM Tris-HCl, pH 7.4, 1% (v/v) Triton X-100, 4 M urea, 0.25
M NaCl containing a protease inhibitor cocktail (Sigma-Aldrich),
followed by incubation at 4uC overnight. Following centrifugation,
the supernatants were applied to DEAE-Sephacel columns
equilibrated in 50 mM Tris-HCl, pH 7.4, 0.3 M NaCl. The
columns were extensively washed with the same buffer and were
then eluted with the same buffer containing 1.5 M NaCl. Eluates
were desalted, lyophilized and digested with chondroitinase ABC
(Seikagaku, Tokyo, Japan) and benzonase (Merck, San Diego,
CA). The digests were then re-applied to DEAE-Sephacel to
remove degraded chondroitin sulfate and oligonucleotides [25].
The HSPG fractions eluted with 1.5 M NaCl were pooled for
further analysis.
Characterization of HS molecular structure
Gel chromatography of HSPGs and HS free chains was
preformed on a Superose 12 column eluted with 50 mM Tris-
HCl, pH 7.4, 1 M NaCl, 0.1% Triton X- 100. To analyze domain
organization, HS samples were subjected to cleavage at N-sulfated
GlcN residues by treatment with nitrous acid at pH 1.5, followed
by reduction with NaB[
3H]4 [25]. The reduced products were
separated by gel chromatography on a column (16200 cm) of Bio-
Gel P-10 (Bio-Rad, Hercules, CA) in 0.5 M NaCl. A portion of the
nitrous acid degradation products was applied to a Sephadex G-15
column and disaccharides were recovered. After desalting and
concentration, the
3Ho r
35S labeled disaccharides, derived from
N-sulfated domains, were further analyzed by anion-exchange
HPLC on a Partisil-10 SAX column, as previously described [8].
Biochemical analysis
Urine samples (25 ml) were analyzed for total protein and
creatinine content, using the automated Kodak 250 system [26].
Blood samples (25 ml) were examined for creatinine, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), and
alkaline phosphatase (ALP) content, using an automated Kodak
950 system [26].
Mammary gland whole mount histostaining
Whole-mount mammary glands, prepared as described [27],
were fixed in Tellys fixative (100 ml EtOH 70%, 5 ml formalin, 5
ml glacial acetic acid), rehydrated and stained with hematoxylin
for 3 h. After staining, the glands were washed in tap water (1 h),
dehydrated and stored in methyl salicylate.
Matrix metalloproeinase analysis
Real-time quantitative PCR analysis was performed with an
automated rotor gene system RG-3000A (Corbett research,
Sydney, Australia). The PCR reaction mix (20 ml) was composed
of 10 ml QPCR sybr master mix (finnzymes, Espoo, Finland), 5 ml
of diluted cDNA (each sample in a six-plicate) and a final
concentration of 0.3 mM of each primer. PCR conditions were as
follows: an initial denaturation step at 95uC for 15 min; 40 cycles
of denaturation at 94uC for 15 s, hybridization at 57uC for 30 s,
and elongation at 72uC for 30 s. The primers used for this reaction
are summarized in Table 2. Actin primers were used as an internal
standard. The expression level of different MMPs in the wt tissue
was regarded as 100%, and the MMP levels in the Hpse-KO mice
were calculated relative to this value.
Western blot analysis
For immunoblot analysis, aliquots of tissue extracts (50 mg) were
separated by electrophoresis in 10% SDS-polyacrylamide gel (PAGE)
and transferred to Immobilon-P membrane (Millipore, Bedford,
MA). MMP2 was detected by anti-mouse MMP2 monoclonal
antibodies 801B (1:150, kindly provided by Dr. Rafael Fridman,
Wayne State University,Detroit, MI).b-cateninwas detected by anti-
mouse monoclonal antibody (1:150, BD transduction laboratories,
San Jose, CA), and anti mouse a-tubulin clone B-5-1-2 (1:5000;
sigma). Membranes were incubated with primary antibodies for 2 h
at room temperature, washed in TTBS and probed with HRP-
conjugated secondary antibody (Jackson Laboratories, Bar Harbor,
ME). After several washes in TTBS, detection of the secondary
antibodies was performed using the SuperSignal Chemiluminescent
Substrate system (Pierce, Rockford, IL). The chemical illumination
signals were exposed to Fuji medical X-ray film (Super RX).
Figure 1. Targeted disruption of the heparanase gene and generation of heparanase deficient mice. A. Structure of the 59 end of the
heparanase (Hpse) gene (top-normal allele), the targeting vector (middle- K/O allele), and the expected size of products obtained by digestion with
Sca1 or EcoRv (bottom). The orientation of the neo cassette and the southern blot probes are indicated. B. Southern blot analysis. Genomic DNA was
extracted from embryos of the intercross of Hpse +/2 heterozygous mice and subjected to Southern blot analysis after digestion with ERv. Wild type
(wt) embryos exhibited only the normal allele, heterozygous embryos exhibited both the normal and the mutated allele, while Hpse-KO mice
exhibited only the shorter, KO allele. Samples were hybridized with the external probe 3, shown in A. C. Heparanase mRNA expression. RNA was
extracted from lungs and spleens of wt and Hpse-KO mice and subjected to PCR analysis of heparanase expression using 3 different PCR primer pairs
designed to amplify different regions of the Hpse gene, as indicated. Heparanase expression was identified in samples derived from wt but not from
Hpse-KO mice. D. Heparanase activity. Blood samples derived from 4 wt and 4 Hpse-KO mice, as well as total cell lysate derived from JAR cells, were
incubated (16 h, 37uC, pH 6.2) with sulfate labeled ECM. Labeled degradation products released into the incubation medium were subjected to gel
filtration analysis on Sepharose 6B, as described in ‘‘Materials and Methods’’. High heparanase activity was noted only in samples derived from wt
mice; no heparanase activity was detected in Hpse-KO samples or JAR cell lysate. E. HS degradation. Liver, kidney and spleen tissue extracts derived
from wt and Hpse-KO mice were prepared as described in ‘‘Materials and Methods’’ and incubated (18 h, 37uC, pH 5.8) with
3H-acetyl labeled HS. The
reaction mixture was then subjected to gel chromatography on Superose-12. The upper panel shows blank (peak I; control
3H-acetyl labeled HS
substrate) and positive control (control substrate treated with recombinant heparanase; peak II). Incubations of Hpse-KO tissue extracts (black)
resulted in the same elution profile as the blank incubation (upper panel), indicating no detectable heparanase activity. In contrast, incubations with
wt tissue extracts (purple) resulted in substantial cleavage of the HS substrate, similar to incubation with recombinant heparanase (upper panel).
doi:10.1371/journal.pone.0005181.g001
Table 1. PCR primers.
Gene sequence (59R39)
L-19 S: 59-ATGCCAACTCTCGTCAACAG-39
AS: 59-GCGCTTTCGTGCTTCCTT-39
Hpse 59 S: 59-CGACCGACGACGTGGTAGAC-39
AS: 59-GCAACAGCTCCTGGAAGGG-39
Hpse middle S: 59-TTTCTGAGCTCTGATGCGCTG-39
AS: 59-TGGGCCTTTCACTCTTGACAG-39
Hpse 39 S: 59-ACTTGAAGGTACCGCCTCCG-39
AS: 59-GAAGCTCTGGAACTCGGCAA-39
doi:10.1371/journal.pone.0005181.t001
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Aortic ring assay was performed as previously described [28].
Briefly, 1 mm mouse aortic rings were embedded in 3-dimensional
growth factor depleted Matrigel (BD Biosciences, San Jose, CA), and
incubated in 0.5 ml Bio-MPM (Biological industries, Beit haemek,
Israel) in the absence or presence of added FGF-2 (50 ng/mL). The
rings were maintained for 6 days (37uC, 8% CO2, humidified
atmosphere), and both the medium, and FGF-2 were replaced every
2 days. Vascular sprouting was evaluated every day for a period of 6
days, then fixed with 4% formalin for 24 h and stained with 0.02%
crystal violet in ethanol (Sigma-Aldrich), and photographed using a
Nikon Eclipse TS 100 phase-contrast microscope.
Matrigel plug assay
Matrigel plug assay was performed as described [29]. Briefly, mice
were injected subcutaneously with 200 mL of growth factor depleted
Matrigel, supplemented with FGF-2 (80 ng/mL). Seven days later,
the Matrigel plugs were excised, photographed, homogenized in a
hypotonic lysis buffer (250 ml of 0.1% Brij-35/plug) and centrifuged
for 5 min at 5,000 g. The supernatant was used in duplicates to
measure hemoglobin with Drabkin’s reagent [30].
Chromatin immunoprecipitation
Chromatin Immunoprecipitation assay was performed as
described [31]. Briefly, cross-linking between DNA and protein
was preformed by adding formaldehyde (Merck) directly into the
culture medium of mouse embryonic fibroblasts (MEF) derived
from wt and Hpse-KO mice. After fixation and lysis, DNA pellets
were sonicated into chromatin fragments of an average length of
,500 bp. ChIP was performed with anti-b-catenin monoclonal
antibody (1:150, BD transduction laboratories, San Jose, CA)
preincubated with magnetic bead-conjugated mouse immunoglob-
ulin G (IgG) (Dynabeads M-280 sheep anti-mouse IgG, Dynal
Biotech ASA) at 4uC, overnight with rotation. Elution of extensively
washed immune complexeswascarried outby the additionof 50mL
of elution buffer [50 mmol/L Tris-HCl (pH 8), 10 mmol/L EDTA,
1% SDS] at 65uC for 15 min with brief vortexing every 2 min [31].
Reverse cross-linking was carried out by incubating at 65uC for
overnight. RNA and unbound proteins were removed by the
addition of 0.2 mg/mL RNase A for 1 h at 37uC, followed by the
addition of 0.2 mg/mL proteinase K for 2 h at 55uC. Recovered
chromatin was suspended in 50 mL TE buffer [31]. Quantitative
PCR analysis was performed using 5 mL of immunoprecipitated
chromatin or input chromatin using Dynamo sybr master mix
(Finnzymes, Espoo, Finland). Amplifications were done using
specific primer sets flanking the putative Lef/Tcf motifs in the
MMP-14 promoter. MMP14-Pro1: sense 59-ttccccacccccacacacaa-
39, antisense 59-caggaataaagccaggtaggaa-39, MMP14-Pro2: sense
59-ctacccaggcagttcacactt-39, antisense 59-caagagggttgtatgctgaga-39.
Statistical Analysis
InStat statistical software, version 3.05 (GraphPad Software,
San Diego, CA), was used to calculate statistical differences
between groups (tested by the paired Student’s t test). All P values
were two-sided.
Results
Targeted disruption of the heparanase (Hpse) gene
We have generated heparanase deficient mice through targeted
interruption of the gene in ES cells. A targeting vector was
constructed to create a functional mutation by deleting the minimal
promoter region (about 500 bp upstream of the transcription start
point) and the entire first exon (Fig. 1A). Following electroporation,
screening of 400 neo-resistant ES clones resulted in two homologous
recombinations in the Hpse gene, identified by Southern blot
analysis, with no additional integration sites. Microinjection of both
clones into C57BL/6 blastocysts yielded chimeric animals, one of
which showed germ line transmission. Breeding of the chimeric
mouse with C57BL/6 strain yielded heterozygous mice which did
not show any overt defects.
Genotypic analysis of offsprings from intercrosses between
heterozygous littermates (Fig. 1B) showed essentially Mendelian
heritance, indicating no early embryonic death. To confirm
complete interruption of the Hpse gene, we examined the
expression of heparanase mRNA derived from different tissues
of wt and Hpse-KO mice by real time PCR using specific primers
as summarized in Table 1. The primers were designed to amplify
the 59, middle, and 39 regions of the heparanase gene. As shown in
figure 1C, heparanase mRNA was detected only in samples
derived from wt mice, but not in samples from the Hpse-KO mice.
To verify the elimination of heparanase enzymatic activity, we
analyzed 4 blood serum samples and 3 tissues from wt and Hpse-
KO mice using sulfate labeled intact ECM (Fig. 1D) or soluble HS
side chains (Fig. 1E) as substrates. Regardless of the assay system,
none of the samples from Hpse-KO mice showed heparanase
activity, while the wt samples exhibited normal levels of
heparanase activity (Fig. 1D and E). The degradation pattern
exhibited by Hpse-KO derived serum samples is identical to that
Table 2. Real Time PCR primers.
Gene sequence (59R39)
Human
Actin S: 59-TCCCTGGAGAAGAGCTACG-39
AS: 59-GTAGTTTCGTGGATGCCACA-39
Hpse S: 59-TACCTTCATTGCACAAACACTG-39
AS: 59-ACTTGGTGACATTATGGAGGTT-39
MMP2 S: 59-GCGGCGGTCACAGCTACTT-39
AS: 59-CACGCTCTTCAGACTTTGGTTCT-39
MMP9 S: 59-CCTGGAGACCTGAGAACCAATC-39
AS: 59-CCACCCGAGTGTAACCATAGC-39
MMP14 S: 59-CGCTACGCCATCCAGGGTCTCAAA-39
AS: 59-CGGTCATCATCGGGCAGCACAAAA-39
MMP25 S: 59-AGTTGCTGTCCAGCCTCAGT-39
AS: 59-CCAAAGTCTCCTGCCTTCTG-39
Mouse
Actin S: 59-ATGCTCCCCGGGCTGTAT-39
AS: 59-CATAGGAGTCCTTCTGACCCATTC-39
MMP2 S: 59-AGCGTGAAGTTTGGAAGCAT-39
AS: 59-CACATCCTTCACCTGGTGTG-39
MMP9 S: 59-AGACGACATAGACGGCATCC-39
AS: 59-GTGGTTCAGTTGTGGTGGTG-39
MMP14 S: 59-GCCTGGAACATTCTAACGA-39
AS: 59-CTTTGTGGGTGACCCTGACT-39
MMP25 S: 59-GCTGACTCGCTATGGCTACC-39
AS: 59-GTCATTGGGTCCATTTGTCC-39
Hpa2 S: 59-GTCCGTGGCTCTATCACACTTT-39
AS: 59-CCTCAGAGTCCCAGCCAGTTT-39
doi:10.1371/journal.pone.0005181.t002
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shown to have no heparanase activity due to extensive promoter
hypermethylation [32]. Of particular significance is the lack of
heparanase activity in serum samples containing activated platelets
and white blood cells known to express exceedingly high levels of
the enzyme [33]. As demonstrated in figure 1D, blood samples
derived from wt mice exhibited high levels of heparanase activity,
as detected by the large amount of low molecular weight material
eluted in fractions 20–40 (Fig. 1D, peak II). Labelled fragments
eluted in peak II were shown to be degradation products of HS, as
they were 5–6 fold smaller than intact HS chains of HSPGs,
resistant to further digestion with papain and chondroitinase ABC,
and susceptible to deamination by nitrous acid [34]. In contrast,
blood samples derived from Hpse-KO mice exhibited no hepar-
anase activity as revealed by the lack of HS degradation fragments
(peak II) and the release of high molecular weight material eluted
in fractions 5–10 (peak I, Fig. 1D). This material, representing
nearly intact HSPGs, is produced by proteolytic cleavage of the
proteoglycan core protein by proteases residing in the ECM and
cell lysate [35]. Similarly, there was no cleavage of
3H-labeled HS
upon incubation with extracts of liver, kidney and spleen derived
from Hpse-KO mice (peak I) vs. a significant degradation of HS
upon incubation with the corresponding wt tissue extracts (peak II,
Fig. 1E). Altogether, these data clearly demonstrate complete
elimination of heparanase enzymatic activity in the Hpse-KO mice.
Phenotypic analysis of the Hpse-KO mice
The homozygous mutant animals showed no obvious aberrant
phenotype, were fertile and exhibited a normal life span. To
examine any possible age-related phenotypes, 6-, 12- and 18-
month old mice were sacrificed and organs were dissected and
fixed in a solution containing 96% ethanol, 1% glacial acetic acid
and 3% distilled water. Paraffin embedded tissue sections were
stained with hematoxilin and eosin. Histological examination of
sections derived from the brain, heart, liver, lung, kidney and
spleen did not reveal significant structural or pathological
abnormalities in the Hpse-KO mice (not shown).
Molecular structure of HS
As degradation of HS is the major function of heparanase, we
first examined the size of HS derived from selected organs. For this
purpose, adult mice were metabolically labeled with Na2
35SO4
and total HS was isolated and subjected to gel filtration
chromatography. As demonstrated in figure 2, HS chains from
Hpse-KO liver (Fig. 2A, B) and kidney (Fig. 2C, D) were of higher
molecular mass in comparison to HS extracted from wt tissues
(Fig. 2). In addition, the elution peaks of free HS chains isolated
from Hpse-KO tissues appeared narrower and more symmetrical
(Fig. 2B,D), indicating less heterogeneity in size distribution in
comparison with the elution profile of HS side chains isolated from
wt tissues (the overall broad size of peaks reflects the state of HS
biosynthesis). Structural analysis of HS sulfation and disaccharide
composition did not show a detectable difference between samples
derived from wt and Hpse-KO tissues (not shown).
Biochemical analysis
To examine the role of heparanase and effect of HS structural
alternations on liver and kidney function, blood samples were
taken from 15 wt and 15 Hpse-KO mice, before and after a 72h
fasting. Samples were analysed for total protein and contents of
Figure 2. Molecular structure of HS from wt vs. Hpse-KO mice. Total metabolically
35S-labeled HSPGs was isolated as described in ‘‘Materials
and Methods’’. The samples were analyzed on a Superose 12 column as shown for liver (A) and kidney (C). The HSPGs were treated with alkali and the
released free HS chains were analyzed on the same column as show for liver (B) and kidney (D). (Blue- wt; red- Hpse-KO). Standard heparin is eluted at
a volume of 14 ml.
doi:10.1371/journal.pone.0005181.g002
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ferase (ALT), and alkaline phosphatase (ALP). No significant
differences between wt and Hpse-KO mice were detected, both
before and after fasting (data not shown). Furthermore, since
platelets contain high amount of heparanase, blood samples were
also examined for coagulation properties (i.e., APTT). Again, there
was no significant difference between the Hpse-KO and wt mice
(not shown).
Mammary gland morphogenesis
We have previously reported that transgenic virgin mice over-
expressing the human heparanase gene (hpa-tg mice) exhibited
abnormal abundant branching of ducts in the mammary gland
and precocious alveolar structures, typical of pregnant mice [36].
Notably, these differences decreased during late stages of
pregnancy and during involution and did not affect the function
of the mammary gland. To our surprise, a similar morphology was
noted in the mammary glands of 3-month old virgin homozygous
Hpse-KO mice (Fig. 3, right panels), as compared to poorly
developed mammary glands seen in the wt virgin mice (Fig. 3, Left
panels). However, unlike the hpa-tg vs. control mice [36], there was
no significant difference between the wt and Hpse-KO mice in the
width of the primary ducts.
Endothelial sprouting and angiogenesis
The involvement of heparanase in cell migration and
angiogenesis is well documented [19]. We have, therefore,
evaluated the effect of heparanase knockout on endothelial cell
migration and sprouting. First, we applied an ex vivo aortic ring
assay. Briefly, 8 wt and 8 Hpse-KO mice were sacrificed and their
aortas were cleaned and cut into 1–2 mm thick rings. The rings
were embedded in growth factor-depleted Matrigel and examined
for endothelial sprouting upon simulation with FGF-2 (50 ng/ml).
As expected, in the absence of FGF-2 there was little or no
sprouting in either the wt or Hpse-KO rings (not shown). Upon
stimulation with FGF-2, both wt and Hpse-KO rings showed
endothelial sprouting (Fig. 4A). Notably, Hpse-KO derived rings
exhibited a more pronounced sprouting (Fig. 4A, right panels)
compared to wt aortic rings (Fig. 4A, left panels), suggesting an
increased response to FGF-2 stimulation.
To validate the ex vivo results, we performed an in vivo
angiogenesis assay. For this purpose, Matrigel supplemented with
FGF-2 was implanted subcutaneously and formation of a capillary
network within the Matrigel implants was visualized. Seven days
after implantation, mice (n=8) were sacrificed and the plugs were
evaluated for neovascularization by measuring the content of
hemoglobin in the Matrigel plug. A profound angiogenic response
was induced by Matrigel-embedded FGF-2 in the Hpse-KO mice
(Fig. 4B, bottom) compared with wt mice (Fig. 4B, top),
corroborating the ex-vivo results. Determination of hemoglobin
revealed a 2.6-fold increase in the hemoglobin content of Matrigel
plugs embedded in Hpse-KO compared to wt mice (55.7567.18
mg/dl vs. 2166.25 mg/dl; p#0.0002, respectively) (Fig. 4B, right).
Interrelation between heparanase and MMPs
The unexpected result of abnormal mammary gland morphology
and increased neovascularization in Hpse-KO mice led us to search
for a possible explanation for this phenotype. The immediate
question was whether other ECM degrading enzyme(s) were
compensating for the lack of heparanase expression. Hpa2, a gene
exhibiting significant homology (,38%) to the heparanase gene
[37], but lacking a detectable heparanase enzymatic activity, was
the first candidate to examine. For this purpose, total RNA
extracted from the kidney, liver and mammary gland of Hpse-KO
and wt mice, was analyzed using specific primers corresponding to
Hpa2 (Table 2). Analysis of Hpa2 expression in the different tissues
revealed no significant difference between wt and Hpse-KO mice
(Fig. 5). These results were further corroborated by Western blot of
Hpa2 showing no difference in protein level between Hpse-KO and
wt mice (not shown). Moreover, the increased HS length found in
Hpse-KO mice does not support upregulation of additional
heparanase-like enzyme. Taking into account that matrix metallo-
proteinases (MMPs) play important roles in rearranging the ECM
structure and thereby in tissue remodeling, morphogenesis and
neovascularization, we investigated the expression of MMPs (real-
time PCR) in the Hpse-KO vs. wt mice. For this purpose, the RNA
samples were further analyzed using specific primers corresponding
to MMP-2, -3, -9, -14 and -25 (Table 2). The results (Fig. 6A)
indicated that the lack of heparanase expression was associated with
marked changes in the expression levels of several members of the
MMP family. MMP-2 was over-expressed (2–3.5 fold) in all samples
extracted from Hpse-KO vs. wt mice. MMP-14 was over-expressed
(4–7 fold) in the liver and kidney, but down regulated (,4 fold) in
mammary glands derived from Hpse-KO vs. wt mice. MMP-9 and
MMP-25 expression levels were altered, albeit to a lower extent,
depending on the tissue (Fig. 6A).
These results were further corroborated by Western blot
analysis revealing increased levels of the MMP-2 protein in
homogenized samples extracted from the liver, kidney and
mammary glands of Hpse-KO vs. wt mice (Fig. 6B). We also
investigated whether the increased expression of MMP-2 is
manifested by elevated MMP-2 enzymatic activity. For this
purpose, plasma samples derived from wt and Hpse-KO blood
were subjected to zymography and evaluated for MMP-2 activity.
MMP-2 activity was approximately 3 fold higher in plasma
samples derived from Hpse-KO vs. wt mice (Fig. 6C).
Next, we sought to investigate a possible molecular pathway
involved in the interaction between heparanase and MMPs. Since
b-catenin was previously implicated in MMP regulation [38,39],
we evaluated its content and staining pattern in tissues derived
from wt and Hpse-KO mice by examining b-catenin accumulation.
Western blot analysis of tissue extracts revealed accumulation of b-
catenin in the soluble fraction of liver, kidney and mammary
glands derived from Hpse-KO compared to wt mice (Fig. 6B,
middle panel). Similarly, immunostaining of kidney tissue sections
derived from wt and Hpse-KO mice (Fig. 6D) revealed a marked
increase in b-catenin staining in Hpse-KO kidneys, corroborating
the Western blot results.
Figure 3. Morphological appearance of mammary glands from
wt vs. Hpse-KO mice. Whole-mount preparations of mammary glands
from 3-month-old virgin mice were stained with hematoxylin. Hpse-KO
derived mammary glands (right panel) showed abundant side branches
and alveolar structures compared with glands from age-matched wt
animals (left panel).
doi:10.1371/journal.pone.0005181.g003
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apply chromatin immunoprecipitation (ChIP) analysis to test
whether b-catenin binds directly to the MMP promoter. For this
purpose, murine embryonic fibroblasts (MEF) derived from Hpse-
KO and wt mice were first examined for MMP expression. As
demonstrated in figure 7A, MMP-9 was 2 fold over expressed and
MMP-2 was 4-fold under expressed in Hpse-KO compared to wt
derived MEF. MMP-14 exhibited a marked 30 fold increased
expression in Hpse-KO MEF and thus was chosen for ChIP
analysis. Matinspector 2.2 promoter analysis software [40]
revealed two putative binding sites for the Lef/Tcf motif in the
murine MMP-14 promoter, at positions 2473 and 21057 from
the transcription starting point (Fig. 7B). Following chemical cross-
linking, chromatin was isolated from Hpse-KO and wt MEF, as
described in ‘Materials and Methods’. The cross-linked chromatin
was sonicated to #500-bp fragments and immunoprecipitated
with anti b-catenin antibody. DNA obtained from the immuno-
precipitated chromatin was amplified using two sets of MMP-14
promoter-specific primers (MMP14-Pro 1 & 2), flanking the two
putative Lef/Tcf motifs (Fig. 7B), as well as a set of primers specific
to the unrelated actin gene sequence, to normalize for equal
chromatin amounts. Quantitative real time PCR revealed a 3–4
fold enrichment of MMP-14 promoter sequences in the two Lef/
Tcf sites of Hpse-KO vs. wt MEF (Fig. 7C). No enrichment was
observed when antibody directed against an irrelevant protein (Flt-
1 tyrosine kinase receptor) was used for the ChIP analysis (data not
shown). These results indicate direct binding of b-catenin to
MMP-14 gene regulatory sequences.
To further investigate the interrelation between heparanase and
MMPs, we transfected human breast carcinoma MDA-NB-231
cells, normally expressing moderate levels of heparanase [22], with
either active or double mutant heparanase (active site Gln 225 and
Gln 343 replaced by Ala) lacking enzymatic activity [41]. Both, the
active and inactive mutant heparanase were ,30 fold over-
expressed in the Hpse-transfected cells as compared to mock
transfected cells (Fig. 8A). As demonstrated in Fig. 8B, cells
transfected with active heparanase exhibited a marked decrease in
expression of MMP-2 (5.8 fold), MMP-9 (6.5 fold) and MMP-14 (3
fold), a mirror image of the increased expression found in Hpse-
KO mice. In contrast, transfecting the MDA-231 cells with the
double mutant inactive heparanase did not affect MMP expression
(Fig. 8B), indicating that heparanase enzymatic activity is involved
in the observed regulation of MMP expression.
Discussion
HS glycosaminoglycans bind to and assemble ECM proteins
(i.e., laminin, fibronectin, collagen type IV) and thereby contribute
Figure 4. Endothelial sprouting and angiogenesis. A. FGF-2 induced vascular sprouting in the aortic ring model. Hpse-KO and wt derived aortic
rings were subjected to FGF-2 induced vascular sprouting for 6 days. The rings were then fixed, stained with 0.02% crystal violet and evaluated for
vascular sprouting. A more extensive endothelial sprouting was noted in Hpse-KO derived rings (right panel) as compared to wt derived rings (left
panel). B. Matrigel plug assay. Hpse-KO (lower panels) and wt (upper panels) mice were injected subcutaneously with 200 ml of growth factor
depleted Matrigel supplemented with FGF-2 (80 ng/ml). Seven days later, the Matrigel plugs were excised and photographed, followed by
homogenization and determination of hemoglobin content using Drabkin’s reagent (right). A pronounced angiogenic response was noted in Hpse-
KO vs. wt mice (5567.18 mg/dl vs. 2166.2 mg/dl; p#0.0002, respectively).
doi:10.1371/journal.pone.0005181.g004
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play important roles in cell-cell and cell-ECM interactions
[2,42,43,44], as well as in physiological and pathological processes
such as tissue morphogenesis and repair, vascularization and
cancer metastasis [1,2,3]. Over expression of heparanase, the
predominant HS degrading enzyme, in transgenic mice and tumor
tissues resulted in pronounced structural alterations of HS [25].
Heparanase is therefore expected to exert significant effects on
embryonic development and tissue morphogenesis and function.
Here, we describe, for the first time, the generation of
heparanase null mice. Southern blot analysis revealed specific
integration of the vector, thereby deleting a part of the promoter
and the first exon. This specific integration resulted in complete
abolishment of heparanase mRNA expression and enzymatic
activity, as revealed by PCR analysis applying 3 different pairs of
primers and lack of heparanase enzymatic activity in blood
samples and tissue extracts of the Hpse-KO mice. Generation of
heparanase KO mice was further demonstrated by biochemical
analysis revealing longer and more homogenous HS chains in
Hpse-KO compared to wt mice. This molecular profile of HS is a
mirror image of that found in heparanase over-expressing
transgenic mice [36]. There were no significant differences in
sulfation level and disaccharide composition.
HS structure and composition are known to affect embryonic
development and tissue remodelling [45,46]. Surprisingly, either
shorter or longer HS chains failed to significantly affect embryonic
development and life span of our Hpse transgenic or null mice,
suggesting a large degree of flexibility in HS chain length in
affecting organ development and tissue function. The fact that HS
chains were longer and that there was no apparent degradation of
HS in the Hspe-KO mice further supports the notion that
heparanase is the predominant and likely only functional
endoglycosidase capable of degrading HS.
Previous studies implicated heparanase in various normal and
pathological processes ranging from bone remodelling, hair
growth and kidney function to cancer metastasis, inflammation
and angiogenesis [14,19,29,47,48,49]. Heparanase is thought to
act both as a hydrolytic enzyme, facilitating cell migration and
release of ECM-resident bioactive factors, and as a signalling
molecule, independent of its enzymatic activity [19,50,51].
Nevertheless, the Hpse-KO mice appeared normal, phenotypically
and histologically, exhibiting a normal litter size and life
expectancy. There were no detectable differences between the
Hpse-KO and wt mice in platelet, kidney and liver functions, nor in
their response to insults such as hepatectomy, delayed type
hypersensitivity (DTH) reaction or wound healing (our unpub-
lished results). Unexpectedly, we noticed an increased angiogenic
response, both ex-vivo and in-vivo, and over branching of ducts in
mammary glands of the Hpse-KO vs. their wt counterpart mice.
The lack of a major phenotype in the Hpse-KO mice could be
attributed to changes in the expression levels of MMP family
members, primarily MMP-2 and MMP-14, observed in the Hpse-
KO mice. MMPs (i.e., MMP-2, MMP-14, MMP-9) degrade the
ECM and, similar to heparanase, release bioactive molecules that
are stored in the ECM, including, for example, pro-angiogenic
factors such as FGF-2, VEGF and HGF [52,53,54]. MMPs,
particularly stromolysin, are also involved in morphogenesis and
over branching of the mammary gland [55]. It is therefore
conceivable that MMPs may compensate for the lack of
heparanase activity and hence mask some of the effects associated
with its deficiency. In fact, at least 14 different MMP knockout
mice have been generated, all of which survived to birth and
exhibited notably subtle phenotypes [54]. This observation was
attributed to the fact that MMPs have many overlapping
substrates in vitro, resulting in a possible redundancy in vivo. Unlike
the large number of MMPs, a single functional heparanase
appears to be used by cells to degrade the HS side chains of
HSPGs, making it an ideal target for gene disruption. The present
study suggests that heparanase, despite of having a different type of
substrate, may, in some aspects, share redundancy with MMP
family members by virtue of its action on a common global
substrate, namely the extracellular matrix and basement mem-
brane.
The observed accumulation of b-catenin in Hpse-KO tissues and
the increased occupation of the MMP-14 promoter by b-catenin,
suggest a possible molecular pathway linking heparanase and
MMPs. b-Catenin, previously implicated in regulating the
expression of MMP-7 [56,57], MMP-14 [38], MMP-2 and
MMP-9 [39], is a central mediator in the canonical Wnt signaling
cascade involved in developmental processes [58]. It is conceivable
that ECM remodelling and tissue morphogenesis in the Hpse-KO
mice are mediated by activation of the b-catenin pathway and the
associated upregulation of MMPs.
Over-expression of heparanase in breast carcinoma cells (MDA-
MB-231) was associated with a marked decrease in the expression
of MMP family members, yielding a mirror image of the results
obtained with the Hpse-KO mice. Notably, this effect was
dependent on heparanase enzymatic activity. Thus, when the
cells were transfected with mutant heparanase lacking enzymatic
activity, there was no change in MMP expression. It should be
noted that not all MMPs are upregulated in response to
heparanase gene silencing. Thus, unlike liver and kidney, we
observed, for example, a decrease in MMP-14 and MMP-25 in the
mammary glands of Hpse-KO mice (not shown), suggesting that a
tissue specific co-regulation of heparanase and MMPs should be
taken into account. Similarly, it appears that in a given tissue some
MMPs are upregulated while other can be downregulated in
Figure 5. Hpa2 expression. RNA samples derived from liver, kidney
and mammary glands of wt and Hpse-KO mice were subjected to
quantitative real time PCR analysis to evaluate the expression of Hpa2.
The expression level determined for each MMP in the wt tissue (blue)
was regarded as 100% and the corresponding expression level
determined in the Hpse-KO tissue (purple) is presented as percentage
relative to the 100% value. Each reaction was repeated 6 times and the
mean6SD is indicated. No significant difference was detected in Hpa2
expression between wt and Hpse-KO mice.
doi:10.1371/journal.pone.0005181.g005
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mice and subjected to quantitative real time PCR analysis to evaluate the expression of MMP-2, MMP-9, MMP-14 and MMP-25. The expression level
determined for each MMP in the wt tissue (blue) was regarded as 100% and the corresponding expression determined in the Hpse-KO tissue (Purple)
are presented as percentage relative to it. Each reaction was repeated 6 times and the mean6SD is indicated. B. Western blot analysis. Liver, kidney
and mammary gland tissue extracts, prepared as described in ‘‘Materials and Methods’’, were subjected to Western blot analysis using anti-mouse
MMP-2 monoclonal antibodies (mA801B; upper panels), anti mouse b-catenin (mAb610154; middle panels), or anti mouse a-tubulin (B-5-1-2; lower
panels). Higher protein levels of MMP-2 and b-catenin were detected in samples derived from Hpse-KO vs. wt tissues. C. MMP2 zymography. Serum
samples derived from Hpse-KO and wt mice were evaluated for MMP-2 activity. MMP-2 activity was approximately 3 fold higher in plasma samples
derived from Hpse-KO vs. wt mice. D. b-catenin immunostaining. Parafin embedded kidney tissue sections were subjected to immunostaining with
antibody directed against b-catenin. Increased staining was observed in kidney derived from Hpse-KO vs. wt mice. C. MMP2 zymography. Serum
samples derived from Hpse-KO and wt mice were evaluated for MMP-2 activity. MMP-2 activity was approximately 3 fold higher in plasma samples
derived from Hpse-KO vs. wt mice.
doi:10.1371/journal.pone.0005181.g006
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heparanase and MMP-9 expression was recently demonstrated
in myeloma cells [59]. In this system, however, transfection of
heparanase into myeloma cells, or addition of recombinant active
heparanase enhanced their expression of pro MMP-9 in vitro and
knockdown of heparanase expression in wt myeloma cells reduced
the level of MMP-9 expression. This effect is likely mediated by
ERK signaling [59]. Regardless of the mode of action, it appears
that heparanase may function as a master regulator of protease
expression and activity within tissues and the tumor microenvi-
ronment during the course of tissue morphogenesis and tumor
progression. The newly identified interrelation between the two
types of distinct ECM degrading enzymes, MMPs which degrade
proteins and heparanase degrading HS saccharide chains, suggests
a co-regulatory mechanism that affects the expression of both
types of enzymes. It appears that a common cellular sensor
monitors the need for ECM remodelling and regulates the balance
between heparanase and MMP expression. It is conceivable that
this putative sensor is activated upon release from the ECM depot,
and, as proposed in our study, regulates MMP expression via the
b-catenin pathway.
Unexpectedly, both overbranching of mammary glands and the
enhanced angiogenic response observed in the Hpse-KO mice
resembled the phenotype seen in heparanase over-expressing
Figure 7. MMP expression and ChIP analysis for b-catenin in MEF cells derived from Hpse-KO and wt mice. A. Real-time PCR. RNA was
extracted from MEF derived from wt and Hpse-KO mice and subjected to quantitative real time PCR analysis to evaluate the expression of MMP-2,
MMP-9, and MMP-14. The expression level determined for each MMP in the wt tissue (blue) was regarded as 100% and the corresponding levels
determined in the Hpse-KO cells (purple) are presented as percentage relative to it. Each reaction was repeated 6 times and the mean6SD is
indicated. B. Schematic representation of regions along the murine MMP-14 promoter with $95% homology to the consensus Lef/Tcf motif.
Numbers show the location of putative Lef/Tcf motifs relative to the transcription initiation site (bent arrow). C. ChIP analysis. Following cross-linking
of proteins to DNA, chromatin derived from Hpse-KO and wt MEF was sonicated into fragments of average length #500 bp; the b-catenin protein was
immunoprecipitated with anti b-catenin antibody, and PCR analysis was performed on the immunoprecipitated DNA samples using primer sets
MMP14-Pro1 & Pro2, as described in ‘Materials and Methods’. Samples were equilibrated for DNA loading amounts using primers specific to actin. The
results are representative of three independent experiments.
doi:10.1371/journal.pone.0005181.g007
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the fact that both mammary morphogenesis and the angiogenic
process involve massive ECM remodelling. In both the Hpse-KO
and hpa-tg mice, regulation of heparanase expression levels
appears to be compromised by up- and down- regulation of
MMPs, respectively. The overall end morphological appearance is
the net result of the balance and co-regulation of ECM-degrading
enzymes such as heparanase and MMPs.
Heparanase has been previously shown to affect gene
expression. We have demonstrated, for example, that over-
expression of the heparanase gene and even exogenous addition
of recombinant heparanase, up-regulate the expression of VEGF
[51] and tissue factor [60]. Applying the hpa-tg and Hpse-KO
mouse models, we have demonstrated up-regulation [60] and
down-regulation (our unpublished results) of tissue factor levels, in
vivo. Preliminary gene array studies indicate that other genes are
affected, as well. It has also been demonstrated that nuclear
translocation of heparanase is associated with induction of gene
expression and cell differentiation [61,62]. It is, therefore, not
surprising that heparanase gene silencing and/or over expression
affect the expression of other ECM-degrading enzymes such as
MMPs.
Numerous studies emphasize the involvement of MMPs and
heparanase in disease situations associated with cancer metas-
tasis, angiogenesis and inflammation [14,15,19,52,54]. Hence,
the observed regulatory association between heparanase and
members of the MMP superfamily may have important clinical
implications. A major effort is invested in developing specific
inhibitory molecules and strategies targeting heparanase [63,64]
and MMPs [65,66]. Clinical trials evaluating the therapeutic
potential of MMP inhibitors yielded disappointing results, in part
due to redundancy among family members, compensating for
the inhibited target enzyme. The observed up-regulation of
MMPs in response to heparanase gene knockout favours a
combined approach in which heparanase and MMP inhibiting
compounds are co-administered. Our generation of viable Hpse-
KO mice lacking major visible abnormalities is regarded as a
good argument for the development of heparanase-based drugs,
presumably with little or no side effects. However, we cannot
exclude the possibility that subtle, unidentified phenotypes may
cause some side effects, depending on the drug and the target
tissue.
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